Education
About Us
Working with TipRanks
Follow Us
InflaRx NV (IFRX)
NASDAQ:IFRX
Cohort A: Vilobelimab, Cohort B: Paridiprubart, Cohort C: Bevacizumab
Ards, Acute Respiratory Distress Syndrome (Ards), Acute Respiratory Distress Syndrome, Ards (Acute Respiratory Distress Syndrome)
Phase II
Recruiting
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
Nov 20, 2024
―
Cohort A: Vilobelimab
Ards, Acute Respiratory Distress Syndrome (Ards), Acute Respiratory Distress Syndrome, Ards (Acute Respiratory Distress Syndrome)
Phase II
Recruiting
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
Nov 20, 2024
―
Cohort C: Bevacizumab
Ards, Acute Respiratory Distress Syndrome (Ards), Acute Respiratory Distress Syndrome, Ards (Acute Respiratory Distress Syndrome)
Phase II
Recruiting
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
Nov 20, 2024
―
Cohort B: Paridiprubart
Ards, Acute Respiratory Distress Syndrome (Ards), Acute Respiratory Distress Syndrome, Ards (Acute Respiratory Distress Syndrome)
Phase II
Recruiting
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
Nov 20, 2024
―
Csu Lower Dose Treatment, Csu High Dose Treatment, Csu Non Responders Ige - High Dose Treatment, Hs Low Dose Treatment, Hs Medium Dose Treatment, Hs High Dose Treatment
Hidradenitis Suppurativa, Hidradenitis, Chronic Urticaria, Idiopathic
Phase II
Recruiting
Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa
Aug 07, 2024
―
Vilobelimab
Pyoderma Gangrenosum
Phase III
Terminated
Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum
Jun 29, 2023
―
Vilobelimab, Vilobelimab + Pembrolizumab Combination Therapy
Scc - Squamous Cell Carcinoma Of Skin
Phase II
Terminated
Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.
Mar 10, 2021
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does InflaRx NV (IFRX) have in its pipeline
IFRX is currently developing the following drugs: Cohort A: Vilobelimab, Cohort B: Paridiprubart, Cohort C: Bevacizumab, Cohort A: Vilobelimab, Cohort C: Bevacizumab. These drug candidates are in various stages of clinical development as the company works toward FDA approval.